First Business Financial Services Inc. Increases Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

First Business Financial Services Inc. boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.5% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 2,560 shares of the medical research company’s stock after buying an additional 200 shares during the period. First Business Financial Services Inc.’s holdings in Thermo Fisher Scientific were worth $1,584,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. BDF Gestion bought a new stake in Thermo Fisher Scientific in the 2nd quarter valued at $6,368,000. Nisa Investment Advisors LLC lifted its position in Thermo Fisher Scientific by 6.2% during the third quarter. Nisa Investment Advisors LLC now owns 140,708 shares of the medical research company’s stock valued at $87,093,000 after purchasing an additional 8,180 shares during the last quarter. Seven Eight Capital LP purchased a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at about $1,161,000. ORG Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 216.6% in the 2nd quarter. ORG Partners LLC now owns 1,640 shares of the medical research company’s stock valued at $890,000 after purchasing an additional 1,122 shares during the last quarter. Finally, CWM LLC boosted its stake in shares of Thermo Fisher Scientific by 9.5% during the 2nd quarter. CWM LLC now owns 18,358 shares of the medical research company’s stock worth $10,152,000 after purchasing an additional 1,590 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $533.02 on Friday. Thermo Fisher Scientific Inc. has a twelve month low of $463.99 and a twelve month high of $627.88. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The company has a market cap of $203.88 billion, a PE ratio of 33.42, a price-to-earnings-growth ratio of 3.58 and a beta of 0.79. The company’s 50 day moving average is $589.87 and its 200 day moving average is $583.04.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The company had revenue of $10.60 billion during the quarter, compared to analysts’ expectations of $10.63 billion. During the same period last year, the business earned $5.69 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up .2% on a year-over-year basis. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.29%. The ex-dividend date of this dividend is Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.78%.

Analyst Ratings Changes

Several research analysts have issued reports on the company. JPMorgan Chase & Co. boosted their target price on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research report on Friday, September 20th. Stephens started coverage on Thermo Fisher Scientific in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 target price on the stock. Evercore ISI lowered their target price on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Wells Fargo & Company decreased their price objective on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. Finally, UBS Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a report on Monday, September 16th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $649.33.

Insider Activity

In related news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $1,120,320.00. Following the completion of the transaction, the senior vice president now directly owns 12,736 shares of the company’s stock, valued at approximately $7,134,197.76. This represents a 13.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the sale, the executive vice president now owns 16,663 shares of the company’s stock, valued at $9,333,946.08. This trade represents a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 37,150 shares of company stock worth $20,651,865 over the last 90 days. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.